Efficacy and safety of alirocumab for regulating blood lipid and reducing cardiovascular events:a systematic review
-
摘要: 目的:评价阿利西尤单抗调节血脂和减少心血管事件的有效性与安全性,为其临床应用提供循证参考。方法:计算机检索PubMed、Embase、Cochrane Library、中国知网、维普、万方等数据库,检索时限均为建库至2020年2月,纳入阿利西尤单抗与安慰剂或阳性药物比较的随机对照试验(RCT),筛选文献,提取资料后采用Cochrane系统评价员手册5.1.0提供的偏倚风险评估工具进行质量评价,采用Stata 16.0软件进行Meta分析。结果:纳入23个RCT共26 404例患者。Meta分析结果显示,阿利西尤单抗降低低密度脂蛋白胆固醇(LDL-C)的百分比显著高于安慰剂(WMD=-56.56,95%CI:-60.17~-52.95,P=0.000)和依折麦布(WMD=-31.57,95%CI:-34.15~-28.98,P=0.000);与安慰剂相比,阿利西尤单抗可显著减少主要不良心血管事件(MACE)(RR=0.86,95%CI:0.79~0.93,P=0.000),但与依折麦布(RR=1.03,95%CI:0.62~1.70,P=0.913)相比差异无统计学意义。安全性方面,阿利西尤单抗的总不良反应发生率与安慰剂和依折麦布相比均无统计学差异,全因死亡率均显著低于安慰剂和依折麦布(均P<0.05),仅局部注射部位反应发生率较安慰剂有所增加(P<0.05)。结论:阿利西尤单抗能显著降低LDL-C,并有效减少心血管事件的发生,不良反应轻微可耐受。Abstract: Objective:To evaluate the efficacy and safety of alirocumab for regulating blood lipid, reducing cardiovascular events,and providing evidence-based references for the clinical application.Method:Randomized controlled trials(RCTs) about the efficacy and safety of alirocumab versus placebo/positive controls were retrieved from PubMed,Embase,Cochrane Library,CNKI,VIP and Wanfang database from their establishment to February 2020.After literature selection and data extraction,quality assessment of included literature were performed using the bias risk assessment tool provided by the Cochrane System Evaluator Manual 5.1.0.Meta-analysis was performed by Stata 16.0 software.Result:A total of 23 RCTs with 26 404 patients were included.Meta-analysis results showed that the percentage of LDL-C decreased by alirocumab was significantly greater than both the placebo [WMD=-56.56,95%CI:(-60.17,-52.95),P=0.000] and ezetimibe [WMD=-31.57,95%CI:(-34.15,-28.98),P=0.000].Compared with placebo,alirocumab significantly reduced major cardiovascular events(MACE)(RR=0.86,95%CI:0.79-0.93,P=0.000),but the difference was not statistically significant compared to ezetimibe(RR=1.03,95%CI:0.62-1.70,P=0.913).In terms of safety,the incidence of total adverse events in the alirocumab group was not statistically different compared to the placebo and ezetimibe group. However, the all-cause mortality in the alirocumab group was significantly lower than that in the placebo and ezetimibe group(both P<0.05). In contrast, it is just that the local injection-site reaction rate in the alirocumab group was increased compared to placebo with statistically significant difference(P<0.05).Conclusion:Alirocumab can significantly decrease LDL-C and reduce cardiovascular events,and adverse events are mild and tolerable.
-
Key words:
- alirocumab /
- hypercholesterolemia /
- dyslipidaemia /
- cardiovascular events
-
-
[1] 胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
[2] 2014年中国胆固醇教育计划血脂异常防治建议专家组,中华心血管病杂志编辑委员会,血脂与动脉粥样硬化循证工作组,等.2014年中国胆固醇教育计划血脂异常防治专家建议[J].中华心血管病杂志,2014,42(8):633-636.
[3] 刘鑫,钟小燕,范清泽,等.Bempedoic acid治疗血脂异常疗效与安全性的系统评价[J].临床心血管病杂志,2019,35(12):1089-1093.
[4] Stroes ES,Thompson PD,Corsini A,et al.Statin-associated muscle symptoms:impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment,Aetiology and Management[J].Eur Heart J,2015,36(17):1012-1022.
[5] Swerdlow DI,Preiss D,Kuchenbaecker KB,et al.HMG-coenzyme A reductase inhibition,type 2 diabetes,and bodyweight:evidence from genetic analysis and randomised trials[J].Lancet,2015,385(9965):351-361.
[6] Teramoto T,Kiyosue A,Ishigaki Y,et al.Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin:ODYSSEY NIPPON[J].J Cardiol,2019,73(3):218-227.
[7] Han Y,Chen J,Chopra VK,et al.ODYSSEY EAST:Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China,India,and Thailand[J].J Clin Lipidol,2020,14(1):98-108.e8.
[8] Schwartz GG,Steg PG,Szarek M,et al.Alirocumab and cardiovascular outcomes after acute coronary syndrome[J].N Engl J Med,2018,379(22):2097-2107.
[9] Koh KK,Nam CW,Chao TH,et al.A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)[J].J Clin Lipidol,2018,12(1):162-172.e6.
[10] Leiter LA,Cariou B,Muller-Wieland D,et al.Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk:The ODYSSEY DM-INSULIN randomized trial[J].Diabetes Obes Metab,2017,19(12):1781-1792.
[11] Teramoto T,Kobayashi M,Uno K,et al.Efficacy and safety of alirocumab in Japanese subjects (Phase 1 and 2 Studies)[J].Am J Cardiol,2016,118(1):56-63.
[12] Teramoto T,Kobayashi M,Tasaki H,et al.Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins-ODYSSEY JAPAN Randomized Controlled Trial[J].Circ J,2016,80(9):1980-1987.
[13] Stroes E,Guyton JR,Lepor N,et al.Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy:The ODYSSEY CHOICE II Study[J].J Am Heart Assoc,2016,5(9):e003421.
[14] Roth EM,Moriarty PM,Bergeron J,et al.A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin:ODYSSEY CHOICE I[J].Atherosclerosis,2016,254:254-262.
[15] Moriarty PM,Parhofer KG,Babirak SP,et al.Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis:the ODYSSEY ESCAPE trial[J].Eur Heart J,2016,37(48):3588-3595.
[16] Ginsberg HN,Rader DJ,Raal FJ,et al.Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher[J].Cardiovasc Drugs Ther,2016,30(5):473-483.
[17] Farnier M,Jones P,Severance R,et al.Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients:The ODYSSEY OPTIONS II randomized trial[J].Atherosclerosis,2016,244:138-146.
[18] Robinson JG,Farnier M,Krempf M,et al.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1489-1499.
[19] Moriarty PM,Thompson PD,Cannon CP,et al.Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients,with a statin rechallenge arm:The ODYSSEY ALTERNATIVE randomized trial[J].J Clin Lipidol,2015,9(6):758-769.
[20] Kereiakes DJ,Robinson JG,Cannon CP,et al.Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy:The ODYSSEY COMBO I study[J].Am Heart J,2015,169(6):906-915.e13.
[21] Kastelein JJ,Ginsberg HN,Langslet G,et al.ODYSSEY FH I and FH II:78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia[J].Eur Heart J,2015,36(43):2996-3003.
[22] Cannon CP,Cariou B,Blom D,et al.Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins:the ODYSSEY COMBO II randomized controlled trial[J].Eur Heart J,2015,36(19):1186-1194.
[23] Bays H,Gaudet D,Weiss R,et al.Alirocumab as add-on to atorvastatin versus other lipid treatment strategies:ODYSSEY OPTIONS I Randomized Trial[J].J Clin Endocrinol Metab,2015,100(8):3140-3148.
[24] Roth EM,Taskinen MR,Ginsberg HN,et al.Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:results of a 24 week,double-blind,randomized Phase 3 trial[J].Int J Cardiol,2014,176(1):55-61.
[25] Stein EA,Gipe D,Bergeron J,et al.Effect of a monoclonal antibody to PCSK9,REGN727/SAR236553,to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy:a phase 2 randomised controlled trial[J].Lancet,2012,380(9836):29-36.
[26] Roth EM,Mckenney JM,Hanotin C,et al.Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia[J].N Engl J Med,2012,367(20):1891-1900.
[27] Mckenney JM,Koren MJ,Kereiakes DJ,et al.Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease,SAR236553/REGN727,in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy[J].J Am Coll Cardiol,2012,59(25):2344-2353.
[28] Seidah NG,Awan Z,Chretien M,et al.PCSK9:a key modulator of cardiovascular health[J].Circ Res,2014,114(6):1022-1036.
[29] 陆言巧,沈兰,何奔.PCSK9抑制剂的机制及其临床进展[J].临床心血管病杂志,2020,36(1):14-19.
[30] Awan Z,Seidah NG,Macfadyen JG,et al.Rosuvastatin,proprotein convertase subtilisin/kexin type 9 concentrations,and LDL cholesterol response:the JUPITER trial[J].Clin Chem,2012,58(1):183-189.
[31] Li H,Wei Y,Yang Z,et al.Safety,tolerability,pharmacokinetics,and pharmacodynamics of alirocumab in healthy Chinese subjects:A Randomized,Double-Blind,Placebo-Controlled,Ascending Single-Dose Study[J].Am J Cardiovasc Drugs,2020.doi:10.1007/s40256-020-00394-1.
[32] Ray KK,Leiter LA,Muller-Wieland D,et al.Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia:The ODYSSEY DM-DYSLIPIDEMIA randomized trial[J].Diabetes Obes Metab,2018,20(6):1479-1489.
[33] 李和教,钟小燕,杨旭平,等.alirocumab添加治疗血脂异常随机对照临床试验的系统评价[J].中国新药与临床杂志,2016,35(6):412-418.
[34] 陈瑾瑾,张倩,潘希丁,等.PCSK9抑制药Alirocumab治疗血脂异常有效性的Meta分析[J].药物流行病学杂志,2017,26(11):729-735.
-
计量
- 文章访问数: 730
- PDF下载数: 295
- 施引文献: 0
下载: